The state of Florida currently has 40 active clinical trials seeking participants for Parkinson's Disease research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
NCT02071134
Recruiting
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated. Additionally, the utilization of the DBS Illumina 3D feature that may be... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: University of Florida Shands Hospital, Gainesville, Florida +4 locations
Conditions: Parkinson's Disease
Register for Updates
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
NCT06976268
Recruiting
A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
08/08/2025
Locations: Site-038, Atlantis, Florida +1 locations
Conditions: Parkinson Disease
Register for Updates
A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease
NCT06773962
Recruiting
The primary objectives of this study are to assess the efficacy of TB006 in improving motor function and to assess the safety of TB006 in participants with Parkinson's Disease (PD).
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
08/06/2025
Locations: Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida +2 locations
Conditions: Parkinson's Disease (PD)
Register for Updates
A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease
NCT06822517
Recruiting
This trial is a randomized, double-blind, placebo-controlled Phase 1b study evaluating the safety/tolerability, PK, and pharmacodynamics of VENT 02, administered orally at 1 dose level twice daily (BID) over 28 days in patients with mild to moderate Parkinson's disease. The study includes a screening period, a 28-day double-blind treatment period, and a 7-day follow-up period after last dose. Approximately 30 patients will be randomized into 1 of the 2 treatment arms.
Gender:
ALL
Ages:
Between 45 years and 90 years
Trial Updated:
08/06/2025
Locations: Investigative Site, Aventura, Florida +11 locations
Conditions: Parkinson Disease
Register for Updates
Neurophysiology of Locomotor Adaptation and Freezing of Gait in Parkinson's Disease
NCT06911229
Recruiting
Locomotor adaptation will be studied using an established split-belt treadmill paradigm, consisting of baseline (1:1 speed ratio), split-belt adaptation (2:1) and post-adaptation (1:1) walking. Split-belt walking will be performed under DBS ON and DBS OFF conditions, while off-medication.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/05/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Parkinson Disease
Register for Updates
Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease
NCT06621602
Recruiting
This study aims to assess the levels of phosphorylated alpha-synuclein (P-SYN) in patients with Parkinson's disease and REM Behavior Disorder using a minimally invasive skin punch biopsy. It seeks to understand the natural progression of P-SYN deposition over time to explore the potential of P-SYN quantification as a biomarker for disease progression.
Gender:
ALL
Ages:
Between 50 years and 100 years
Trial Updated:
08/04/2025
Locations: Aventura Neurologic Associates, LLC, Aventura, Florida +1 locations
Conditions: REM Behavior Disorder, Parkinson Disease
Register for Updates
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
NCT06809400
Recruiting
The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
07/31/2025
Locations: K2 Medical Research, LLC, Maitland, Florida +4 locations
Conditions: Parkinson Disease
Register for Updates
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
NCT06553027
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 or 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
07/29/2025
Locations: Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida +6 locations
Conditions: Parkinson Disease
Register for Updates
A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
NCT06680830
Recruiting
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway. Participants will: • Take NEU-411 or placebo every day for 52 weeks
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
07/29/2025
Locations: Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida +3 locations
Conditions: Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
Register for Updates
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
NCT06602193
Recruiting
This Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled, parallel-group study, followed by an OLE, is designed to evaluate the safety, tolerability, and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD. LRRK2-PD is defined as Parkinson's Disease (PD) in individuals who are heterozygous or homozygous carriers of a pathogenic LRRK2 variant that increases LRRK2 kinase activity.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
07/28/2025
Locations: Parkinson's Disease and Movement Disorders Center, Boca Raton, Florida
Conditions: Parkinson Disease
Register for Updates
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
NCT06765668
Recruiting
The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Visionary Investigators Network, Aventura, Florida +5 locations
Conditions: Parkinson Disease
Register for Updates
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
NCT06285643
Recruiting
The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.
Gender:
ALL
Ages:
Between 45 years and 75 years
Trial Updated:
07/23/2025
Locations: Parkinson's Disease and Movement Disorders Center of Boca Raton (Neurology), Boca Raton, Florida +1 locations
Conditions: Parkinson Disease
Register for Updates